Pharmaceutical manufacturers of Aclidinium bromide

MSN Group is the fastest growing research-based pharmaceutical company based out of India. Founded in 2003 with a mission to make health care affordable, this Hyderabad-based venture has Fifteen API and Six finished dosage facilities established across India & USA. The group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals to make them more accessible.

OLON Group is a prominent worldwide firm specializing in the creation and manufacture of active pharmaceutical ingredients for CDMO and Generics. It serves as a dependable and preferred partner for the pharmaceutical, biotech, and specialty ingredients sectors. With a 2021 turnover of 580 million dollars, OLON provides 300 APIs for the Generic market. The company benefits from a workforce of 2,300 employees, including a highly skilled R&D team of over 300 individuals. This enables OLON to offer comprehensive integrated packages and services to facilitate the full development of APIs, leveraging extensive expertise in both Chemical and Biological processes, all within a full cGMP and regulatory framework. OLON holds approximately 160 active US DMFs and 79 granted CoS. OLON's headquarters is located in Rodano, near Milan, Italy, and it operates 11 manufacturing facilities - 8 in Italy, 1 in Spain, 1 in the USA, and 1 in India. These facilities are designed in accordance with the most stringent international standards. Additionally, OLON has 3 branch offices in Hamburg (Germany), Florham Park, NJ (USA), and Shanghai (China).

R L Fine Chem Pvt. Ltd. was established in 1984 in Bengaluru and it was one of the first companies to develop and manufacture psychotropic substances in the country. In 2016, private equity groups acquired the company and are targeting a CAGR of over 20 percent for the future. The company today operates out of its 2 facilities one is at Gauribidnaur in Karnataka and the other one at Hindupur in Andhra Pradesh. Our commitment to pursue excellence and an uncompromising attitude towards quality has helped us emerge as leaders in the manufacture of psychotropic substances and APIs in other therapeutic segments such as Antipsychotics, Antihistamines, and Muscle relaxants. We are currently exporting our API to over 80 countries globally in addition to the Indian market.

Harman Finochem Limited is an India-based Pharmaceutical Company catering to its clients across the globe. Established by Mr. Bhupinder Singh Manhas in 1983, our core competencies are in manufacturing and exporting of Active Pharmaceutical Ingredients mainly Metformin HCl, Fenofibrate, Divalproex Sodium, Riboflavin Phosphate Sodium, Glycopyrrolate/Glycopyrronium bromide and more.

Hovione brings over six decades of experience as a CDMO and serves as a specialized integrated provider delivering solutions for drug substance, drug product intermediate, and drug product. With four FDA examined facilities in the United States, China, Ireland, and Portugal, as well as research laboratories in Portugal and the United States, the company supplies pharmaceutical customers with services for the development and compliant production of innovative drugs, including highly potent compounds. Hovione delivers a comprehensive range of development services and manufacturing capabilities in particle engineering such as Spray Drying.

Inke S.A., a wholly owned subsidiary of Neuraxpharm, has been dedicated to the development and production of high-quality Active Pharmaceutical Ingredients (APIs) with intricate synthesis processes, primarily for application in respiratory and central nervous system (CNS) therapies since 1980. The company, based in Barcelona (Spain) and with over two decades of expertise in micronization, has been continuously expanding internationally since 1998, supplying APIs globally, including the US, Europe, and Japan. Inke has been consistently recognized for its quality and has undergone successful inspections by major global authorities, with the most recent US-FDA inspection taking place in May 2019. Over the past twenty years, the company has made significant progress in establishing itself as a reputable provider of respiratory APIs for inhalation.